[Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer]
- PMID: 14716136
- DOI: 10.1159/000076168
[Current status and perspectives of chemotherapy for anthracycline-pretreated breast cancer]
Abstract
Randomized trials performed in anthracycline-pretreated breast cancer patients have demonstrated good activity of taxane-based regimens. In a face to face comparison, single-agent docetaxel proved to be significantly more effective than paclitaxel. Treatment with docetaxel was also associated with an increased incidence of grade grade-3/4 toxicities in this trial. Antitumor activity of taxane-based combination regimens was clearly superior to single-agent therapy in two trials. As anticipated, treatment-associated toxicity was greater with combination regimens, but this did not affect quality of life.
Copyright 2003 S. Karger GmbH, Freiburg
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials